Table III.
Chemotherapy regimens and efficacy of the first-line chemotherapy treatment for small bowel adenocarcinoma.
| Regimen | Number of patients (%) |
|---|---|
| First-line chemotherapy | |
| mFOLFOX6 | 14 (51.9) |
| CAPOX | 4 (14.8) |
| TS-1 ± CDDP | 7 (25.9) |
| 5-FU + LV | 1 (3.7) |
| CPT-11 + CDDP | 1 (3.7) |
| Platinum-containing 1st line chemotherapy treatment (yes/no) | 24 (88.9)/3 (11.1) |
| Molecular-targeted agent-containing 1st line chemotherapy treatment (yes/no) | 6 (22.2)/21 (77.8) |
| Combined-radiation therapy treatment (yes/no) | 2 (7.4)/25 (92.6) |
| Efficacy of 1st line chemotherapy (CR/PR/SD/PD) | 2 (7.4)/8 (29.6)/12 (44.5)/5 (18.5) |
| Response rate (RR)/Disease control rate (DR) | 10 (37.0%)/22 (81.5%) |
| Molecular-targeted agent-containing 1st or 2nd line chemotherapy treatment (yes/no) | 8 (7, bevacizumab; 1, cetuximab,1) |
| (29.6)/19 (70.4) |
n=27. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; mFOLFOX6, oxaliplatin, leucovorin and 5-fluorouracil regimen; CAPOX, oxaliplatin and capecitabine regimen; 5-FU, 5-fluorouracil; CDDP, cisplatin; LV, leucovorin; CPT-11, irinotecan.